Infectious disease biomarkers have gained prominence through the COVID-19 pandemic and ongoing challenges from emerging pathogens. These biomarkers support diagnosis, treatment selection, and monitoring of response in patients with infectious diseases. For comprehensive application analysis, refer to the Biomarkers Market report.

Molecular diagnostic biomarkers detect pathogen genetic material with high sensitivity and specificity, enabling rapid diagnosis of infections. PCR tests for respiratory viruses, including SARS-CoV-2, have become essential tools for patient management and public health surveillance. Multiplex panels detect multiple pathogens simultaneously, accelerating diagnosis.

Antigen tests detect pathogen proteins, providing rapid results suitable for point-of-care testing. These tests have been widely deployed for COVID-19 screening, enabling identification of infectious individuals. Antigen tests are also available for other pathogens including influenza, malaria, and HIV.

Serological biomarkers detect antibodies produced in response to infection, providing evidence of past exposure and immune response. During the COVID-19 pandemic, serological testing informed understanding of population immunity and supported vaccine development. Serological biomarkers are essential for diagnosis of chronic infections such as HIV and hepatitis.

Antimicrobial resistance biomarkers identify pathogens resistant to specific antibiotics, guiding treatment selection and supporting antimicrobial stewardship. Rapid resistance testing enables early initiation of effective therapy and reduces use of broad-spectrum antibiotics.

The importance of infectious disease biomarkers reflects the continuing threat from emerging pathogens and the need for rapid, accurate diagnostic tools. As infectious disease challenges evolve, biomarkers will remain essential for patient care and public health.